Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, de Tullio P, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018;558:605-609 pubmed publisher

Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, et al. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity. Oncogene. 2015;34:3164-75 pubmed publisher

Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes P, Iyengar P, et al. Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. J Exp Med. 2018;215:1913-1928 pubmed publisher

Schroyer A, Stimes N, Abi Saab W, Chadee D. MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells. Oncogene. 2017;: pubmed publisher

Ichihara E, Westover D, Meador C, Yan Y, Bauer J, Lu P, et al. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res. 2017;77:2990-3000 pubmed publisher

Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS ONE. 2014;9:e113217 pubmed publisher

Sun B, Kawahara M, Nagamune T. Modeling tandem AAG8-MEK inhibition in melanoma cells. Cancer Med. 2014;3:710-8 pubmed publisher

Fernández I, Blanco S, Lozano J, Lazo P. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer. Mol Cell Biol. 2010;30:4687-97 pubmed publisher

Goel V, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene. 2009;28:2289-98 pubmed publisher